NEWS
G-BA resolutions on afamelanotide for the rare disease erythropoietic protoporphyria RAPS EURO Convergence Europe in Berlin on 7 May 2024
Obstacles for patient access to medicines can happen at different stages of a medicine's life cycle. Therefore, marketing...
Benefit assessment in Germany – G-BA resolutions on Zolgensma Market Access Day in Paris on 2 October 2023
The global community of market access professionals met in France on 2 October 2023 at the Market Access Day – the first...
Spesolimab: Does the benefit assessment of medicines for rare diseases need more flexibility? The case of spesolimab (Spevigo®)
After Boehringer Ingelheim’s announcement to withdraw a medicine for the treatment of a rare skin disease from the German market on...
AMNOG Gene Therapies in Oncology and Beyond Inaugural Meeting of IMAS on 3-5 April 2023 in Miami Beach, USA
Do you know IMAS? IMAS stands for International Market Access Society. As a matter of fact it derives from MAS, the Market Access...
Rare Disease Day 2023 is a tricky day for orphan drugs Sharing colours sometimes takes time
I remember very well the day I asked the G-BA for permission to speak about the specific German benefit assessment of orphan drugs....